SEARCH:   Advanced

Blood, Vol. 113, Issue 18, 4153-4162, April 30, 2009 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood Bassan et al. 113: 4153 Supplemental materials for: Bassan et al Files in this Data Supplement: Table S1. Details of 14 relapsing MRDneg patients (supplementl to Fig. 3) (PDF, 40.2 KB) Figure S1. (A) DFS of CR patients and (B) overall survival of CR patients (supplement to Fig. 2) (JPG, 66.2 KB) - Figure S2. (A) OS and (B) CIR according to MRD study results (supplementl to Fig. 3) (JPG, 63.6 KB) - Figure S3. Univariate prognostic analysis for DFS (JPG, 61.2 KB) - Effect of patient age in (A) different groups and (B) final univariate model with cut-point at 55 years. Figure S4. Univariate prognostic analysis for DFS (JPG, 57.2 KB) - Effect of WBC count in (A) different groups and final univariate models with cut-point at (B) 30 × 109/L and (C) 100 × 109/L. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020